

Sustainability Accounting Standards Board (SASB) Index

//////////Science for a better life

BIOTECHNOLOGY & PHARMACEUTICALS

Sustainability Disclosure Topics & Accounting Metrics

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting
Safety of Clinical Trial	Discussion, by world region, of management process for	HC-BP- 210a.1	Bayer, similar to many major pharmaceutical and biotechnology companies, utilizes clinical research organizations (CROs) to deliver some of our clinical trial portfolio. This is done through two models.
Participants	ensuring quality and patient safety during clinical trials		 The first model is functional service provision where CRO staff are engaged by Bayer in order to supplement internal resources. In this case, the CRO personnel works on clinical trials using Bayer processes and Bayer IT systems. The second model is where Bayer outsources the clinical trial in full. For these situations, we have large, global CROs with extensive geographical reach, which gives Bayer the opportunity to manage them centrally by appropriate integration into Clinical and Study Teams at the global level. Both Bayer and our CROs adhere to Good Clinical Practice (GCP) and country-specific legal, data privacy, ethical (Declaration of Helsinki) and regulatory requirements. To manage our CRO partners and our outsourcing model, a global process is in place applying to all regions. There are three components of the full outsourcing model: Contingent Contracting Model, containing fixed price and bonus/penalty Operating Model, with clear responsibilities and the CRO operating with its own resources, processes and IT systems
			3. Risk-based Oversight Model, with Bayer staff focusing on oversight activities that are critical for overseeing patient safety and data integrity To facilitate the full outsourcing model, Bayer works on industry platforms and to recognized regulatory, industry and data standards.
			With regard to patient safety, assessment and reporting to health authorities, we use Bayer IT systems, people and processes, receiving reports from the investigator. With respect to audit and inspection, these are outlined in our quality agreement, which is appended to the Master Service Agreement, or corresponding supplier agreements. Bayer assesses which clinical sites require audit using a risk-based method. Additional CROs providing supplementary services (e.g. imaging, laboratory analysis) are also utilized and oversight is conducted via a similar mechanism to the full outsourcing model, with Bayer staff focusing on activities that are critical to overseeing patient safety and data integrity.
			Before any activities can be outsourced to a potential CRO, the CRO is subjected to a qualification process. An integral part of this process is a risk- based assessment whether a GCP qualification audit is required.
			Bayer publishes information on clinical trials in compliance with the respective local laws. Bayer publishes information on its own clinical trials both in the publicly accessible registers and in its own Clinical Trial Explorer database. Further information about our globally uniform standards, the monitoring of clinical studies and the role of the ethics committees can be found on our website.
			For more information: // <u>Bayer 2022 Sustainability Report</u> – Chapter 3.8 Product Stewardship – Pharmaceuticals and Consumer Health – Clinical Trials // Clinical Trials website <u>https://pharma.bayer.com/clinical-trials</u> // Ethics in Clinical Trials website <u>https://pharma.bayer.com/worldwide-standards</u> // Bayer Clinical Trials website <u>https://clinicaltrials.bayer.com/</u> // <u>http://www.clinicaltrials.gov/</u>

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting		
	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	HC-BP- 210a.2	During 2022, no US FDA Good Clinical Practice or pharmacovigilance inspections were conducted, either at clinical investigator sites or at company facilities.		
	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	HC-BP- 210a.3	Not reported		
Access to Medicines	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	HC-BP- 240a.1	For more information: // <u>Bayer 2022 Sustainability Report</u> – Sustainability Strategy chapter // <u>Bayer 2022 Sustainability Report</u> – Focus on: Access to Health Care chapter // Access to Medicine Foundation 2022 ranking <u>https://accesstomedicinefoundation.org/access-to-medicine-index/report-cards/bayer-ag</u>		
	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	HC-BP- 240a.2	// Bayer 2022 Sustainability Report – Focus on: Access to Health Care chapter // Access to Medicine Foundation 2022 ranking <u>https://accesstomedicinefoundation.org/access-to-medicine-index/report-cards/bayer-ag</u>		
Affordability & Pricing	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	HC-BP- 240b.1	Not reported		
	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	HC-BP- 240b.2	From 2021 to 2022, the Bayer US portfolio WAC for prescription products increased by 5.1%.		
	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	HC-BP- 240b.3	Not reported		

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting
Drug Safety	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	HC-BP- 250a.1	See FDA Adverse Event Reporting Website
	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	HC-BP- 250a.2	See FDA Adverse Event Reporting Website
	Number of recalls issued, total units recalled	HC-BP- 250a.3	https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts?search_api_fulltext=Bayer&field_regulated_product_field=All (0 for 2022, 1 for 2021) https://www.accessdata.fda.gov/scripts/ires/index.cfm#tabNav_advancedSearch
	Total amount of product accepted for takeback, reuse, or disposal	HC-BP- 250a.4	Whenever possible and within the framework of legal regulations, we make use of the opportunities in our divisions to recycle solvents, catalysts and intermediates and return them to the production process following treatment. For products such as pharmaceuticals and crop protection products, reutilization and recycling are usually prohibited by legislation. The disposal of pharmaceutical products from the Pharmaceuticals and Consumer Health divisions is subject to strict safety criteria. Packaging materials are recycled in line with national regulations as part of the country-specific infrastructure for waste disposal. Through a returns program, we enable doctors' offices and hospitals to send remaining stock or unused supplies of the iodinated X-ray contrast agent Ultravist™ back to us. This in turn makes it possible to properly reuse the iodine in an industrial cycle while at the same time helping to avoid iodine emissions into the environment.
	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	HC-BP- 250a.5	None. All our manufacturing sites are classified as NAI (no action indicated) or VAI (voluntary action indicated) by the FDA.
Counterfeit Drugs	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	HC-BP- 260a.1	// Bayer 2022 Sustainability Report – Chapter 3.5 Product Stewardship – Protection against Product Counterfeiting
	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	HC-BP- 260a.2	// Bayer 2022 Sustainability Report – Chapter 3.5 Product Stewardship – Protection against Product Counterfeiting

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting
	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	HC-BP- 260a.3	In addition to the process established in the quality management system, we have introduced a data management tool for the corporate security and legal functions. This enables assessments and reports to be compiled on activities by law enforcement authorities in connection with pharmaceutical counterfeiting that were triggered by information and analyses we submitted. For more information: // Bayer 2022 Sustainability Report – Chapter 3.5 Product Stewardship – Protection against Product Counterfeiting
Ethical Marketing	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	HC-BP- 270a.1	Not reported
	Description of code of ethics governing promotion of off- label use of products	HC-BP- 270a.2	We do not tolerate any improper exertion of influence on our business partners. As part of our compliance management system, we record and investigate any suspected violation of our responsible marketing principles, irrespective of whether the complaints come from internal or external sources. The most important Bayer Group regulation in this context is our Group Regulation on Anti-Corruption, which is supplemented by the rules of conduct for responsible marketing. Furthermore, we are committed to ethical advertising and communication for all our products and services. Industry codes for pharmaceutical products and medical devices that have been adopted by major national and international associations and organizations also apply to marketing and distribution at Bayer. In many countries, these standards are further underpinned by local codes – all of which apply to prescription pharmaceuticals and some of which also apply to nonprescription medicines, dietary supplements, medical devices and medicated skincare products. All codes of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) serve as a binding minimum global standard for all of Bayer's human pharmaceutical products in their area of application. In addition, Bayer observes the codes of the European Federation of Pharmaceutical products, Bayer complies with the regulations set out in the IFPMA Code of Practice as the minimum global standard, along with those set forth in regional national codes. The aforementioned codes contain provisions governing, among other matters, advertising materials, the distribution of samples, cooperation with members of specialist groups in connection with speaker and consultancy contracts, and scientific studies. Pharmaceuticals observes the applicable transparency rules (e.g. the Physician Payments Sunshine Act in the United States) and participates in voluntary programs such as the EFPIA Disclosure Code. For more information: // Bayer 2022 Sustainability Report– Chapter 2.6 Corporate G
Employee Recruitment, Develop- ment & Retention	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	HC-BP- 330a.1	To maintain an enthusiasm for Bayer among top researchers and scientists, we offer them special development opportunities that are tailored to their requirements. These include new scientific challenges, special advanced training offerings and a career path either as experts or as managers in various Bayer regions, functions or divisions. Through our Science Fellows Community, we talk to our scientific specialists about their own career development. Special mentoring programs are established to support employees' early development and their regular networking with experienced scientists and managers. For more information: // Bayer 2022 Sustainability Report– Chapter 6.6 Employees – Employee Development and Integration

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting				
	(1) Voluntary and (2)	HC-BP-					
	involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others		Fluctuation				
					Voluntary		Total
			%	2021	2022	2021	2022
			Women	6.7	6.2	12.6	12.1
			Men	5.9	5.7	11.8	12.2
			Total	6.2	5.9	12.1	12.2
				uctuation by region and by age group: it <u>y Report –</u> Chapter 6.2 Employees – E	Employee Data		
Supply Chain Management	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	HC-BP- 430a.1	groups, such as Audit Oper Extremely stringent safety development and manufac The quality management sy applicable legal, regulatory registration, production and manufacture of pharmaceu Pharmacovigilance Practice guidelines of the ICH (Inter Internal experts and extern in development and produc providers, our suppliers an corrective measures verifie relevant standards, are reg In addition to the internal of verify compliance with the GMP certificates or in the f	of Rx-360, with representation on the Bo rations, Supply Chain Security, Cell & Ge standards for patients and medical pro- ture of pharmaceuticals and medical do ystem of the Pharmaceuticals and Com- r and ethical requirements for all stages d distribution. These standards particul titcals – such as Good Manufacturing F e (GVP), ISO certifications such as thos national Conference on Harmonization hal assessors regularly conduct risk-base ction as well as for registered product s d contract manufacturers. Observation d at regular intervals. The quality requir jularly reviewed and integrated into our quality assurance mechanisms, all our s various national and international requi form of an official producer permit). All of t <u>ty Report</u> – Chapter 3.8 Product Stewa edical devices	ene Therapy, and Data Inte fessionals apply to pharm evices are subject to very sumer Health divisions is of the provision of a pha larly include the rules for Practice (GMP), Good Dist se for the manufacture of of Technical Requirement sed audits to verify compl specifications. Such audit is made during these audi rements derived from regu- quality management syst sites are regularly inspected irements, and certified acc our sites received the targ	grity. All of our own releva accuticals and medical of strict quality requirement based on internationally rmaceutical or a medical good working practice (G ribution Practice (GDP), medical devices (e.g. ISC s for Registration of Pha- iance with the statutory r s also cover institutes su ts are systematically eva- ulatory requirements, per em. ad by the health authorities cording to the respective geted certifications in 202	Int facilities are taking part in Rx36 evices. That's why both the es. recognized standards and device – from development to xP) in the development and Good Clinical Practice (GCP), Goo 0 17025 and 13485), and the maceuticals for Human Use). equirements and relevant standard boontracted by Bayer, service uated and compliance with mits and authorizations, and from es of the respective countries to product category (e.g. through 22.
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with	HC-BP- 510a.1	Not reported				

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting
	Description of code of ethics governing interactions with health care professionals	HC-BP- 510a.2	We do not tolerate any improper exertion of influence on our business partners. As part of our compliance management system, we record and investigate any suspected violation of our responsible marketing principles, irrespective of whether the complaints come from internal or external sources.
			The most important Bayer Group regulation in this context is our Group Regulation on Anti-Corruption, which is supplemented by the rules of conduct for responsible marketing. Furthermore, we are committed to ethical advertising and communication for all our products and services.
			Industry codes for pharmaceutical products and medical devices that have been adopted by major national and international associations and organizations also apply to marketing and distribution at Bayer. In many countries, these standards are further underpinned by local codes – all of which apply to prescription pharmaceuticals and some of which also apply to nonprescription medicines, dietary supplements, medical devices and medicated skincare products.
			All codes of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) serve as a binding minimum global standard for all of Bayer's human pharmaceutical products in their area of application. In addition, Bayer observes the codes of the European Federation of Pharmaceutical Industries and Associations (EFPIA) in its interaction with healthcare professionals and patient organizations. Regarding the advertising of human pharmaceutical products, Bayer complies with the regulations set out in the IFPMA Code of Practice as the minimum global standard, along with those set forth in regional and national codes.
			The aforementioned codes contain provisions governing, among other matters, advertising materials, the distribution of samples, cooperation with members of specialist groups in connection with speaker and consultancy contracts, and scientific studies. Pharmaceuticals observes the applicable transparency rules (e.g. the Physician Payments Sunshine Act in the United States) and participates in voluntary programs such as the EFPIA Disclosure Code.
			For more information: // <u>Bayer 2022 Sustainability Report</u> - Chapter 2.6 Corporate Governance – Compliance – Marketing compliance // Bayer Responsible Marketing & Sales website <u>https://www.bayer.com/en/sustainability/responsible-marketing-sales-regulation</u> // Bayer Corporate Compliance Policy website <u>https://www.bayer.com/sites/default/files/bayer-corporate-compliance-policy-en.pdf</u>

Activity I	Metrics
------------	---------

SASB Activity Metric	SASB Code	
Number of patients treated		Not reported
Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)		// Bayer 2022 Annual Report – Chapter 1.1.2 Corporate Structure // Bayer 2022 Annual Report – Chapter 1.3 Focus on Innovation – Pharmaceuticals

CHEMICALS

Sustainability Disclosure Topics & Accounting Metrics

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting			
Greenhouse Gas Emissions	Gross global Scope 1 emissions, percentage covered under emissions-	RT-CH- 110a.1	In reporting greenhouse gas emissions, we take account of from our own power plants, vehicles, waste incineration pla whose annual energy consumption exceeds 1.5 terajoules.	the recommendations of the G nts and production facilities (So	reenhouse Gas Protocol (cope 1) are determined at	GHG Protocol). Direct emissions all environmentally relevant sites
	limiting regulations		Greenhouse Gas Emissions (Scope 1 and 2)			
			Million metric tons of CO ₂ equivalents	2020	2021	2022
			Scope 1: Direct emissions ¹	2.01	1.93	1.91
			of which carbon dioxide (CO ₂)	1.96	1.90	1.85
			of which ozone-depleting substances	0.011	0.011	0.011
			of which partially fluorinated hydrocarbons (HFCs)	0.022	0.014	0.039
			of which nitrous oxide (N2O)	0.008	0.007	0.007
			of which methane (CH ₄)	0.003	0.003	0.003
			For more information: // Bayer 2022 Sustainability Report – Chapter 7.4 Climate // Bayer CDP Report Climate www.bayer.com/cdp-climate		Emissions	
	0	RT-CH- 110a.2	We support the Paris Agreement and the objective of limitin climate neutrality at our own sites a Group target for 2030 v (Scope 1 and 2) by 42% (reference year: 2019) in absolute to reduce the relevant emissions in our value chain (Scope 3) b Targets initiative (SBTi). The attainment of these targets is a employees. For more information on our Group targets, plea Bayer has undertaken to achieve a net zero target for green expression of commitment to net zero greenhouse gas emiss in partnership with the UN Global Compact and the We Mea	within our climate program. We terms and partly by offsetting the by 12.3% in absolute terms. The accounted for in the compensat ase see our Sustainability Repo- shouse gas emissions througho assions, the company also signe	plan to attain this target p ne remaining emissions (S ese reduction goals were ion of the Board of Manag rt 2022 – Chapter 7. Clim ut the entire value chain b	partly by reducing our emissions cope 1 and 2). We also strive to confirmed by the Science Based gement and LTI-entitled manageri ate Protection. by 2050 or earlier. As an external
			 // Investment in energy efficiency and renewable energies: million in renewable energies and in increasing the energy more efficient facilities and building technology, and in th production sites. Capital expenditure projects are under energy or emissions-free steam production. // We will offset those of our emissions (Scope 1 and 2) that 	y efficiency of our facilities and ne implementation and optimiza way at various sites to advance	buildings by 2030. We an tion of energy management the use of climate-neutra	re investing in process innovations ant systems, particularly at our Il technologies such as geotherma

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting				
			projects. In this process, we focus on nature-based innovative projects to promote the development of		rning forestry and agricu	ture projects. We will a	also invest in
			In 2022, we looked at the risks and opportunities sten relation to our company and integrate them into our st Enterprise Risk Management (ERM) system.				
			 // Based on the Paris Agreement, the most important countries and regions in which Bayer operates have committed to limit global warming by reducing their greenhouse gas emissions. // One example is the European Union's Green Deal, the goal of which is to accelerate the transition to an emissions-free future and achieve climate neutrality by 2050. Consequently, the EU is expected to further increase costs for the emission of greenhouse gases (e.g. through CO2 regulation such as the EU emissions trading system (EU-ETS) or a carbon tax), adjust financing incentives (e.g. through the EU taxonomy) and drive forward technological changes (e.g. through the promotion of renewable energies and hydrogen technologies). // China has committed to attaining net zero emissions by 2060 and is therefore expected to introduce further regulations in this connection. Through our strategy for achieving climate neutrality and reducing greenhouse gas emissions on the pathway to a 1.5°C scenario, we are reducing the risk of additional costs caused by the expected regulations. For more information: // Bayer 2022 Sustainability Report – Sustainability Strategy chapter // Bayer 2022 Sustainability Report – Chapter 7.2 Climate Protection – Climate Strategy // Bayer 2022 TCFD Report www.bayer.com/tcfd 				ieve climate 2 regulations rive forward tion.
			// Bayer CDP Report Climate www.bayer.com/cdp-cl	imate			
Air Quality	Air emissions of the following pollutants: (1) NO _x (excluding	RT-CH- 120a.1	Other Direct Air Emissions				
	N ₂ O), (2) SO _x , (3) volatile		1,000 metric tons	2020	2021	2022	
	organic compounds (VOCs), and (4) hazardous air		ODS ¹	0.0043	0.0039	0.0042	
	pollutants (HAPs)		VOCs ²	0.69	0.43	0.46	
	,		NO _x (nitrogen oxides)	4.16	3.57	3.52	
			SO _x (sulfur oxides)	1.32	1.28	1.29	
			¹ Ozone-depleting substances (ODS) according to the Montreal Pro ² Volatile organic compounds (VOCs) excluding methane	tocol, in CFC-11 equivalents			
			For more information: // Bayer 2022 Sustainability Report - Chapter 8.2 En	vironmental Protection and Safety -	Air Emissions		

Energy Management (1) Total energy consumed,
(2) percentage grid electricity,
(3) percentage renewable, (4)RT-CH-
130a.1total self-generated energy

Energy Consumption			
TJ	2020	2021	2022
Primary energy consumption	17,836	18,071	17,525
Natural gas	10,911	10,682	10,287
Coal	566	608	571
Liquid fuels	2,901	2,653	2,688
of which for vehicle fleet/transport	2,480	2,194	2,121
Waste	416	499	481
Other ¹	932	1,068	1,162
Primary energy consumption for third-party companies	2,111	2,561	2,335
Secondary energy consumption	18,022	16,764	17,947
Electricity ²	12,166	11,059	12,359
of which electricity from power grid	11,451	8,325	8,33
of which electricity from renewable energies	715	2,734	4,024
Steam	4,485	4,381	4,259
of which steam from renewable energies	25	82	92
Steam from waste heat (process heat)	550	574	558
Cooling energy	691	632	631
Secondary energy consumption for third-party companies	131	118	140
Total energy consumption	35,858	34,835	35,472

¹ For example biomass

² The proportion of primary energy sources used in generating the electricity consumed depends on the respective electricity mix of our energy suppliers.

Primary and secondary energy consumption is usually dependent on the production volume: the more that is produced, the greater the energy consumption and also the associated greenhouse gas emissions. Energy management systems such as ISO 50001 help to identify potential energy savings both in production processes and when developing new production processes or converting existing ones. This not only conserves valuable energy resources, but also takes into account economic factors associated with long-term savings. In our Report to CDP, we also describe the projects to save energy that were implemented at various sites.

Investment in efficiency measures and renewable energies: to achieve an absolute reduction in our remaining emissions, we intend to invest €500 million in renewable energies and in increasing the energy efficiency of our facilities and buildings by 2030.

We are investing in process innovations, more efficient facilities and building technology, and in the implementation and optimization of energy management systems, particularly at our production sites. Capital expenditure projects are underway at various sites to advance the use of climate-neutral technologies such as geothermal energy or emissions-free steam production.

For more information:

// Bayer 2022 Sustainability Report – Sustainability Strategy chapter

- // Bayer 2022 Sustainability Report Chapter 7.2 Climate Protection Climate Strategy
- // Bayer 2022 Sustainability Report Chapter 7.5 Climate Protection Energy
- // Bayer CDP Report Climate www.bayer.com/cdp-climate

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting			
Water	(1) Total water withdrawn, (2)	RT-CH-				
Management	total water consumed,	140a.1	Water Use by Source			
	percentage of each in regions with High or Extremely High		Million m ³	2020	2021	2022
	Baseline Water Stress		Groundwater	21.1	20.6	21.3
			Surface water	15.3	10.1	8.5
			Rainwater	4.0	6.0	2.8
			Drinking water	13.2	15.2	16.7
			Recycled wastewater from third parties	0.8	0.7	0.6
			Other ¹	2.1	1.6	2.2
			Water content of raw materials ²	0.7	0.7	0.7
			Total water use	57	55	53
			of which in water-scarce areas or areas threatened by water scarcity ³	3	3	3
	Number of incidents of non- compliance associated with water quality permits,	RT-CH- 140a.2	For more information: // <u>Bayer 2022 Sustainability Report</u> – Chapter 8.3 Environ // Bayer CDP Report Water <u>www.bayer.com/cdp-water</u> // <u>Bayer 2022 Sustainability Report</u> – Chapter 8.5 Environ			
	standards, and regulations					

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting				
			We aim to identify potential for improvement particularly scarcity, and to use as little water there as possible. The groundwater resources were identified using the Aquedu management systems at all relevant sites in water-scarc relevant Bayer sites here are all locations with annual englobal water consumption. The key characteristics of a sustainable water management conservation of water resources. Due to widely varying I detailed risk analysis that takes into account local circur risks with locally adapted countermeasures such as the wastewater recirculation. These activities are accompan participation in roundtables with regulatory authorities and We are aware that climate change will further exacerbate communities, we plan to establish suitable water manage by 2030. We identify such sites using the base scenario	se regions in which water consumplict Water Risk Atlas of the World R e areas or in areas identified as be ergy consumption of at least 1.5 te ent policy are a balance between v ocal situations, each water manage instances and the main parameters establishment of alternative supply ied by management measures that do residents. The the problem of water scarcity in t ement systems by the end of 2023 of the World Resources Institute (N onmental Protection and Safety – N	ption exceeds the available tesources Institute (WRI). ing threatened by water serajoules that at the same water consumption and a ement system is designed of our water supply and y sources, the improveme include regular employed he future. To avert future at all relevant sites that WRI).	le renewable surface and We had already establishe carcity by the end of 2020 time account for at least vailability, and the optimal d individually on the basis disposal. We address the nt of wastewater quality o e training in water manage risks for our sites and the	d water). The 0.1% our of a identified ment and local
Hazardous Waste	Amount of hazardous waste generated, percentage	RT-CH- 150a.1	Hazardous Waste Generated ¹				
			Hazardous Waste Generated ¹ 1,000 metric tons	2020	2021	2022	
Waste	generated, percentage			2020 305	2021 316	2022 276	
Waste	generated, percentage		1,000 metric tons				
Waste	generated, percentage		1,000 metric tons Total hazardous waste generated	305	316	276	
Waste	generated, percentage		1,000 metric tons Total hazardous waste generated of which from production	305 301 4	316 303	276 273	
Waste	generated, percentage		1,000 metric tons Total hazardous waste generated of which from production of which from construction work	305 301 4	316 303	276 273	
Waste	generated, percentage		1,000 metric tons Total hazardous waste generated of which from production of which from construction work ¹ Definition of hazardous waste in accordance with the local laws in each	305 301 4	316 303	276 273	

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting			
Community Relations	Discussion of engagement processes to manage risks and opportunities associated with community interests	RT-CH- 210a.1	 <u>Bayer 2022 Sustainability Report</u> - Chapter 1.3 The Compan <u>Bayer 2022 Sustainability Report</u> - Chapter 2.2 Corporate Ga <u>Bayer 2022 Sustainability Report</u> - Chapter 2.8 Corporate Ga <u>Bayer 2022 Sustainability Report</u> - Chapter 2.10 Corporate Ga <u>Bayer 2022 Sustainability Report</u> - Chapter 8.8 Environmenta <u>Bayer 2022 Sustainability Report</u> - Chapter 8.10 Environmenta <u>Bayer 2022 Sustainability Report</u> - Chapter 8.10 Environmenta <u>Bayer 2022 Sustainability Report</u> - Chapter 9.2 Giving and Fa 	overnance – Behavioral Prir overnance – Risk Managen Governance – Stakeholder al Protection and Safety – F tal Protection and Safety –	nent Dialogue Plant Safety Emergency and Crisis M	anagement
Workforce Health &	(1) Total recordable incident rate (TRIR) and (2) fatality	RT-CH- 320a.1	Recordable Occupational Injuries ¹			
Safety	rate for (a) direct employees			2020	2021	2022
	and (b) contract employees		Number of occupational injuries	390	443	413
			of which Bayer employees	335	377	365
			of which employees of contractors under direct Bayer supervision	55	66	48
			Overall rate of occupational injuries (RIR ²)	0.32	0.38	0.37
			Rate of occupational injuries with lost workdays (LTRIR ³)	0.20	0.22	0.18
			Fatal occupational injuries ⁴	2	2	1
			Fatal occupational injuries of employees of contractors not under Bayer supervision ⁵	4	4	-
			 ² RIR = Recordable Incident Rate ³ LTRIR = Lost Time Recordable Incident Rate ⁴ Fatal occupational injuries of Bayer employees and employees of contractors in ⁵ These fatalities were not correctly assigned in previous years. The designation ⁶ These fatalities were not correctly assigned in previous years. The designation ⁷ These fatalities were not correctly assigned in previous years. The designation ⁸ These fatalities were not correctly assigned in previous years. The designation ⁹ These fatalities were not correctly assigned in previous years. The designation ⁹ These fatalities were not correctly assigned in previous years. The designation ⁹ These fatalities were not correctly assigned in previous years. The designation ⁹ These fatalities were not correctly assigned in previous years. The designation ⁹ Bayer employees and employees of contractors under the dir As a result, the RIR covers injuries and occupational illnesses be worked, which is equivalent to 413 occupational injuries worldw statistical terms, this means that one recordable incident occurre constituted 204 of the total of 413 occupational injuries, meanin improved slightly from 0.22 in 2021 to 0.18 in 2022. The continue home, which was considerably expanded as a protective measu Regrettably, one employee lost his life in a work-related accident plummeted. The employee died in hospital as a result of his injuries for more information: <i>1</i> Bayer 2022 Sustainability Report – Chapter 8.6 Environmental as the state of the state	a of the group of people involved h dable Incident Rate (RIR), w rect supervision of Bayer le oth with and without lost we ide (2021: 443). The RIR th ed for more than every 542 g that the corresponding p ued low number of occupat ure in connection with the C t in 2022. An employee in A ries.	hich covers all occupatio ading to medical treatme orkdays. In 2022, it was a us came in below the de ,000 hours worked. Reco arameter, the Lost Time I ional injuries was due in OVID-19 pandemic. Argentina was fatally injur	nt that goes beyond basic firs at 0.37 cases per 200,000 hou fined target for 2022 of 0.38. I ordable injuries with lost workd Recordable Incident Rate (LTR part to increased working from ed when a flexible big bag
	Description of efforts to assess, monitor, and reduce	RT-CH- 320a.2	The workplaces of our employees and those of contractors under related risk assessment and hazard analysis by Bayer experts the	•	, , , ,	•

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting
			Measures derived from this analysis to protect the health of our employees follow the STOP hierarchy: 1) substitution, 2) technical protective measures, 3) organizational protective measures and 4) personal protective measures. These measures and targeted studies are designed to prevent occupational illnesses. In addition to the appraisals by Bayer experts, both our employees and those of contractors are urged to immediately report work-related hazards or dangerous situations to their supervisors or via the compliance hotline. As with accidents that have actually occurred, we conduct incident analyses based on these reports to determine suitable measures to prevent serious accidents from occurring as far as possible. On top of country-specific regulations regarding mandatory examinations, we offer our employees regular medical examinations – in some cases on a mandatory basis – in all countries in which this is legally permissible. Within the context of our occupational health, safety and environmental protection management, Bayer employees and employees of contractors receive extensive training in the prevention of accidents and safety incidents and in promoting and maintaining their own health. The measures range from safety briefings and special training courses on the safe handling of chemical substances to web-based training that highlights the advantages and possibilities of a work environment that promotes health. Overall, more than 58,000 employees completed health and safety training measures in 2022. For more information: // Bayer 2022 Sustainability Report – Chapter 8.6 Environmental Protection and Safety – Occupational Health and Safety // Bayer 2022 Sustainability Report – Chapter 8.6 Environmental Protection and Safety – Disosafety <
Product Design for Use-phase Efficiency	Revenue from products designed for use-phase resource efficiency	RT-CH- 410a.1	Global agriculture and food systems are confronted with major challenges, such as climate change (with respect to climate change mitigation as well as climate change adaptation), water scarcity and population growth. Scientists and UN organizations expect the world population to grow to around 10 billion people by 2050 – an increase of around two billion people relative to 2022. In addition, both the Food and Agriculture Organization (FAO) of the United Nations and the World Resources Institute (WRI) envisage a 50% increase in the demand for food and animal feed by 2050. The demand for animal-based protein and thus also for animal feed is expected to increase further, especially in the emerging markets. At the same time, the already limited farmland will decline due to climate change, water problems, soil erosion and other factors. The agricultural sector therefore has to meet the needs of a growing population, while at the same time promoting sustainability and protecting our ecosystems. Intensification leads to less land being required for the same amount of food produced. While agricultural yields have grown by 60% over the past 40 years, the amount of agricultural land has increased by only 5%. This productivity increase was substantially enabled by technological developments in the areas of plant breeding and – since the 1990s – plant biotechnology as well as management practices such as fertilization, irrigation and crop protection. Insecticides and fungicides have played a crucial part in minimizing harvest losses. Crops compete with weeds for water, nutrients and light, resulting in a potential crop loss of up to 30%. Herbicides are an important tool for reducing this growth competition. Bayer helps farmers cultivate more food for a growing population, improving food security while at the same time reducing the environmental impact of agriculture. Digital technologies play an important role here, as do improved seed and good agricultural practices. To reduce harvest losses caused by insect pests, compet

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting
Safety & Environ- mental	(1) Percentage of products that contain Globally Harmonized System of	RT-CH- 410b.1.	The active ingredients we use in most of our finished products, such as pharmaceuticals and crop protection products, are or contain Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Category 1 and 2 Health and Environmental Hazardous Substances. Details on sales from relevant products are published in our Bayer 2022 Annual Report.
Stewardship of Chemicals	Classification and Labeling of Chemicals (GHS) Category 1 and 2 Health and Environmental Hazardous Substances, (2) percentage of such products that have undergone a hazard assessment		Bayer's finished products, such as pharmaceuticals, crop protection products, seeds and biocides, are subject to very stringent regulations prescribing specific and detailed approval and authorization procedures. As a result, our products cannot be sold on the market until they have been approved by a competent authority or an official registration has been granted. As a condition of their approval, the prescribed efficacy and safety of the individual products must always be demonstrated as proven. An approval therefore only applies for a particular product with the formulation registered in the marketing authorization. Changes in the product composition (such as new formulations for crop protection products) require an additional approval or registration. In addition to the regulation of finished products, extensive statutory regulations also apply to the chemical substances handled by Bayer during product manufacture. Chemical substances are subject to the respective regional chemical regulations. These include <u>REACH</u> in the European Union, the <u>Lautenberg Chemical Safety Act</u> (formerly TSCA) in the United States and the Measures for Environmental Management Registration of New Chemical Substances (MEP Order No. 12) of the Ministry of Ecology and Environment (MEE) in China. To fulfill these requirements, we have formulated Group-wide and division-specific regulations.
			For more information: // Bayer 2022 Annual Report – Chapter 1.1.2 Group Structure // Bayer 2022 Annual Report – Chapter 2.2.2 Business Development by Division – Crop Science // Bayer 2022 Sustainability Report – Chapter 3.2 Product Stewardship – Regulatory Conditions // Bayer 2022 Sustainability Report – Chapter 3.6 Product Stewardship – Crop Science // Bayer 2022 Sustainability Report – Chapter 3.8 Product Stewardship – Pharmaceuticals and Consumer Health
	Discussion of strategy to (1) manage chemicals of concern and (2) develop alternatives with reduced human and/or environmental impact	RT-CH- 410b.2	Bayer's finished products, such as pharmaceuticals, crop protection products, seeds and biocides, are subject to very stringent regulations prescribing specific and detailed approval and authorization procedures. As a result, our products cannot be sold on the market until they have been approved by a competent authority or an official registration has been granted. As a condition of their approval, the prescribed efficacy and safety of the individual products must always be demonstrated as proven. An approval therefore only applies for a particular product with the formulation registered in the marketing authorization. Changes in the product composition (such as new formulations for crop protection products) require an additional approval or registration.
			In addition to the regulation of finished products, extensive statutory regulations also apply to the chemical substances handled by Bayer during product manufacture. Chemical substances are subject to the respective regional chemical regulations. These include <u>REACH</u> in the European Union, the <u>Lautenberg Chemical Safety Act</u> (formerly TSCA) in the United States and the Measures for Environmental Management Registration of New Chemical Substances (MEP Order No. 12) of the Ministry of Ecology and Environment (MEE) in China. To fulfill these requirements, we have formulated Group-wide and division-specific regulations.
			For more information: // <u>Bayer 2022 Sustainability Report</u> – Chapter 3.2 Product Stewardship – Regulatory Conditions // <u>Bayer 2022 Sustainability Report</u> – Chapter 3.6 Product Stewardship – Crop Science // <u>Bayer 2022 Sustainability Report</u> – Chapter 3.8 Product Stewardship – Pharmaceuticals and Consumer Health

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting
Genetically Modified Organisms	Percentage of products by revenue that contain genetically modified organisms (GMOs)	 410c.1 of high-value seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions and service for sustainable agriculture. Bayer specializes in high-quality seeds with groundbreaking traits that offer not just higher yields, but also improved weed defense against insects. Our genetically modified plants containing Bacillus thuringiensis (Bt) control specific insect pests a 	Bayer specializes in high-quality seeds with groundbreaking traits that offer not just higher yields, but also improved weed control and more effective defense against insects. Our genetically modified plants containing Bacillus thuringiensis (Bt) control specific insect pests attempting to directly feed on the plant. Our herbicide-tolerant plants are tolerant to certain herbicides such as glyphosate or dicamba. This enables weeds in fields to be eliminated using herbicides without damaging the crops.
			For more information: // Bayer 2022 Annual Report – Chapter 1.1.2 Group Structure // Bayer 2022 Annual Report – Chapter 1.2 Strategy and Targets // Bayer 2022 Annual Report – Chapter 1.3 Innovation – Crop Science // Bayer 2022 Annual Report – Chapter 2.2.2 Business Development by Division – Crop Science // Bayer 2022 Sustainability Report – Focus on: Agriculture chapter
Management of the Legal & Regulatory Environment	Discussion of corporate positions related to government regulations and/or policy proposals that address environmental and social factors affecting the industry	related to530a.1achievement of our financial and nonfinancial objectives. Opportunity and risk management is therefore an integrent regulationsBayer.olicy proposals thatWe have implemented a holistic and integrated risk management system designed to ensure the continued existe the Group through the early identification, assessment and treatment of risks. Our risk management system is ali	We have implemented a holistic and integrated risk management system designed to ensure the continued existence and future target attainment of the Group through the early identification, assessment and treatment of risks. Our risk management system is aligned to internationally recognized standards and principles such as the ISO 31000 standard of the International Organization for Standardization, and is defined and implemented with
			For more information: // Bayer 2022 Annual Report – Chapter 3.2 Opportunity and Risk Report // Bayer 2022 Sustainability Report – Chapter 2.2 Corporate Governance – Behavioral Principles (BASE) // Bayer 2022 Sustainability Report – Chapter 2.3 Corporate Governance – Transparency // Bayer 2022 Sustainability Report – Chapter 2.4 Corporate Governance – Bioethics // Bayer 2022 Sustainability Report – Chapter 2.4 Corporate Governance – Steering and Management Systems // Bayer 2022 Sustainability Report – Chapter 2.6 Corporate Governance – Compliance // Bayer 2022 Sustainability Report – Chapter 2.6 Corporate Governance – Compliance // Bayer 2022 Sustainability Report – Chapter 2.8 Corporate Governance – Risk Management // Bayer 2022 Sustainability Report – Chapter 2.10 Corporate Governance – Stakeholder Dialogue // Bayer 2022 TCFD Report www.bayer.com/tcfd // Bayer Code of Conduct for Responsible Lobbying https://www.bayer.com/en/sustainability/code-of-conduct-for-responsible-lobbying // Bayer Group Positions https://www.bayer.com/en/sustainability/position-biodiversity

	SASB Accounting Metric	SASB Code	Bayer Reporting				
Operational Safety, Emergency Prepared- ness & Response	Process Safety Incidents Count (PSIC), Process Safety Total Incident Rate (PSTIR), and Process Safety Incident Severity Rate (PSISR)	RT-CH- 540a.1	Since 2019, we have used the globally standardized key perform integrated into the Group-wide reporting system. Reporting of th (ICCA). Process safety incidents (PSIs) refer to incidents during v primary containment, such as pipelines, pumps, tanks or drums. 2022, the PSI-R was 0.11 (2021: 0.08). A total of 122 process s In addition, we also indicate the Process Safety Incident Seve Council of Chemical Associations (ICCA).	requirements of the Interr substances or energy that mber of process safety in 2022 (Process Safety Incid	national Council of Chemica exceed defined thresholds cidents per 200,000 hours dent Count, PSI-C).	al Association s leak from the worked. In	
			Process Safety Incidents ¹				
			-	2020	2021	2022	
			Process Safety Incident Count (PSI-C) ¹	92	96	122	
			Process Safety Incident Rate (PSI-R) ^{1,2}	0.08	0.08	0.11	
			Process Safety Incident Severity Rate (PSI-SR) ^{1,3}	0.21	0.14	0.16	
			 ¹ According to ICCA (International Council of Chemical Associations) ² Number of PSI incidents per 200,000 hours worked ³ Degree of severity for all PSI incidents per 200,000 hours worked 				
			For more information.	erious incident can occur.			
	Number of transport incidents	RT-CH- 540a.2	For more information: // Bayer 2022 Sustainability Report – Chapter 8.8 Environmed All of the 17 transport incidents in 2022 constituted road tran materials/dangerous goods (see following table). One of the table also led to severe personal injuries.	ental Protection and Safety	transport incidents, six		
			// Bayer 2022 Sustainability Report – Chapter 8.8 Environmed All of the 17 transport incidents in 2022 constituted road transmaterials/dangerous goods (see following table). One of the table also led to severe personal injuries.	ental Protection and Safety nsport accidents. Of these transport incidents was als	transport incidents, six		
			// Bayer 2022 Sustainability Report – Chapter 8.8 Environmed All of the 17 transport incidents in 2022 constituted road transmaterials/dangerous goods (see following table). One of the table	ental Protection and Safety nsport accidents. Of these transport incidents was als	transport incidents, six		
			// Bayer 2022 Sustainability Report – Chapter 8.8 Environmed All of the 17 transport incidents in 2022 constituted road transmaterials/dangerous goods (see following table). One of the table also led to severe personal injuries.	ental Protection and Safety nsport accidents. Of these transport incidents was als	transport incidents, six o an environmental incid	dent. Two of these transpo	
			 <u>Bayer 2022 Sustainability Report</u> – Chapter 8.8 Environmed All of the 17 transport incidents in 2022 constituted road transmaterials/dangerous goods (see following table). One of the talso led to severe personal injuries. Significant ¹ Transport and Environmental Incidents 202 Crop Science, Luling, USA, January While a generator was being filled up with fuel, diesel 	ental Protection and Safety nsport accidents. Of these transport incidents was als	transport incidents, six to an environmental incidents.	dent. Two of these transpo	
			 <u>Bayer 2022 Sustainability Report</u> – Chapter 8.8 Environmed All of the 17 transport incidents in 2022 constituted road transmaterials/dangerous goods (see following table). One of the table led to severe personal injuries. Significant ¹ Transport and Environmental Incidents 202 Crop Science, Luling, USA, January While a generator was being filled up with fuel, diesel flowed onto a building site. Crop Science, Nigel, South Africa, February A truck whose contents also included a Bayer product 	ental Protection and Safety nsport accidents. Of these transport incidents was als 22 Transport	transport incidents, six to an environmental incidents.	dent. Two of these transpo	

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting			
			Crop Science, East Hawthorn, Australia, July A truck overturned. Drums containing crop protection products fell into a roadside ditch.	Х	_	_
			Crop Science, Beijing, China, August A truck belonging to a transport company and containing Bayer products (crop protection products) caught fire.	Х	_	-
			Crop Science, Muscatine, USA, September Owing to a defective seal, a mixture of methanol and methylamine leaked from a tank.	-	Х	
			Crop Science, Thane, India, November A transporter was struck by a bus. One driver died and crop protection products leaked onto the road.	Х		X
			¹ In accordance with the definition and reporting criteria of the ICCA/Response transport and environmental incidents in connection with the transport of	•		
			For more information: // <u>Bayer 2022 Sustainability Report</u> – Chapter 8.9 Environm	nental Protection and S	Safety – Transportation a	nd Storage Safety

Activity Metrics

SASB Activity Metric	SASB Code	
Production by reportable segment	RT-CH- 000.A	For more information: // <u>Bayer 2022 Annual Report</u> – Chapter 2.2.2 Business Development by Division – Crop Science

AGRICULTURAL PRODUCTS

Sustainability Disclosure Topics & Accounting Metrics

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting			
Greenhouse Gas Emissions	Gross global Scope 1 emissions	FB-AG- 110a.1	See above: Indicator Chemicals – "Greenhouse Gas E regulations – RT-CH-110a.1"	Emissions – Gross global Scope 1 em	issions, percentage cover	red under emissions-limiting
	Discussion of long-term and short-term strategy or plan to manage Scope 1 emissions, emissions reduction targets, and an analysis of performance against those targets	FB-AG- 110a.2	See above: Indicator Chemicals – "Greenhouse Gas E emissions, emissions reduction targets, and an analy			r plan to manage Scope 1
	Fleet fuel consumed, percentage renewable	FB-AG- 110a.3				
	percentage renewable	110a.5	Primary Energy Consumption			0000
			Terajoules Liquid fuels for vehicle fleet/transport	2020 2,480	2021 2,194	2022 2,121
			For more information: // <u>Bayer 2022 Sustainability Report</u> – Chapter 7.5 Cl // Bayer CDP Report Climate <u>www.bayer.com/cdp-c</u>			
Energy Management	(1) Operational energy consumed, (2) percentage grid electricity, (3) percentage renewable	FB-AG- 130a.1	See above: Indicator Chemicals – "Energy Manageme self-generated energy – RT-CH-130a.1"	ent – (1) Total energy consumed, (2) p	ercentage grid electricity,	(3) percentage renewable, (4) tot
Water Management	(1) Total water withdrawn, (2) total water consumed, percentage of each in regions with High or Extremely High Baseline Water Stress	FB-AG- 140a.1	See above: Indicator Chemicals – "Water Managemen or Extremely High Baseline Water Stress – RT-CH-144		I water consumed, percer	ntage of each in regions with Hig
	Description of water management risks and discussion of strategies and practices to mitigate those risks	FB-AG- 140a.2	See: Indicator Chemicals – "Water Management – De risks – RT-CH-140a.3"	scription of water management risks a	and discussion of strategi	ies and practices to mitigate thos

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting
	Number of incidents of non- compliance associated with water quantity and/or quality permits, standards, and regulations	FB-AG- 140a.3	See above: Indicator Chemicals – "Water Management – Number of incidents of non-compliance associated with water quality permits, standards, and regulations – RT-CH-140a.2" For more information: // Bayer 2022 Sustainability Report – Chapter 8.5 Environmental Protection and Safety – Environmental Incidents
Food Safety	Global Food Safety Initiative (GFSI) audit (1) non- conformance rate and (2) associated corrective action rate for (a) major and (b) minor non-conformances	FB-AG- 250a.1	Not applicable
	Percentage of agricultural products sourced from suppliers certified to a Global Food Safety Initiative (GFSI) recognized food safety certification program	FB-AG- 250a.2	Not applicable
	(1) Number of recalls issued and (2) total amount of food product recalled	FB-AG- 250a.3	Not applicable
Workforce Health & Safety	(1) Total recordable incident rate (TRIR), (2) fatality rate, and (3) near miss frequency rate (NMFR) for (a) direct employees and (b) seasonal and migrant employees	FB-AG- 320a.1	See above : Indicator Chemicals – "Workforce Health & Safety – (1) Total recordable incident rate (TRIR) and (2) fatality rate for (a) direct employees and (b) contract employees – RT-CH-320a.1" Seasonal and migrant employees are included. Near miss frequency rate (NMFR) is not reported.
Environ- mental & Social Impacts of Ingredient Supply Chain	Percentage of agricultural products sourced that are certified to a third-party environmental and/or social standard, and percentages by standard	FB-AG- 430a.1	We are a member of the renowned organizations Roundtable on Sustainable Palm Oil (RSPO) and Round Table on Responsible Soy (RTRS). As regards palm oil, we use credits according to the book and claim procedure of the Roundtable on Sustainable Palm Oil (RSPO). Beginning in 2022, we will successively transition to the mass balance supply chain standard of the RSPO. For more information: // Bayer Supplier Management website <u>https://www.bayer.com/en/sustainability/supplier-management</u>
	Suppliers' social and environmental responsibility audit (1) non-conformance rate and (2) associated corrective action rate for (a) major and (b) minor non- conformances	FB-AG- 430a.2	The core principles of our sustainability requirements are established in Bayer's Supplier Code of Conduct, which is based on our Bayer Human Rights Policy, the principles of the UN Global Compact and the core labor standards of the International Labour Organization (ILO). For more information: // Bayer 2022 Sustainability Report – Chapter 4.2 Procurement – Sustainability in the Supply Chain // Bayer 2022 Sustainability Report – Chapter 5. Human Rights // Bayer Supplier Code of Conduct <u>https://www.bayer.com/sites/default/files/2022-12/Supplier-code-of-conduct-english-version-dec-22.pdf</u> // Bayer Supplier Code of Conduct Guidance <u>https://www.bayer.com/sites/default/files/Bayer_Supplier-code-of-conduct-guidance-EN.pdf</u>

SASB Topic	SASB Accounting Metric	SASB Code	Bayer Reporting
	Discussion of strategy to manage environmental and social risks arising from contract growing and commodity sourcing	FB-AG- 430a.3	We expect our suppliers to comply with the requirements of our Supplier Code of Conduct, which is based on our Bayer Human Rights Policy, the principles of the UN Global Compact and the core labor standards of the ILO. For more information: // Bayer 2022 Sustainability Report – Chapter 4. Procurement – Sustainability in the Supply Chain // Bayer 2022 Sustainability Report – Chapter 5. Human Rights // Bayer Supplier Code of Conduct <u>https://www.bayer.com/sites/default/files/2022-12/Supplier-code-of-conduct-english-version-dec-22.pdf</u> // Bayer Supplier Code of Conduct Guidance <u>https://www.bayer.com/sites/default/files/Bayer_Supplier-code-of-conduct-guidance-EN.pdf</u>
GMO Management	Discussion of strategies to manage the use of genetically modified organisms (GMOs)	FB-AG- 430b.1	 Bayer is the world's leading agriculture enterprise, with businesses in crop protection, seeds and traits, and digital farming. We offer a broad portfolio of high-value seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions and extensive customer service for sustainable agriculture. Bayer specializes in high-quality seeds with groundbreaking traits that offer not just higher yields, but also improved weed control and more effective defense against insects. Our genetically modified plants containing Bacillus thuringiensis (Bt) control specific insect pests attempting to directly feed on the plant. Our herbicide-tolerant plants are tolerant to certain herbicides such as glyphosate or dicamba. This enables weeds in fields to be eliminated using herbicides without damaging the crops. Sales are published in the Bayer 2022 Annual Report. For more information: // Bayer 2022 Annual Report - Chapter 1.1.2 Corporate Structure // Bayer 2022 Annual Report - Chapter 1.2 Strategy and Targets // Bayer 2022 Annual Report - Chapter 1.3 Innovation - Crop Science // Bayer 2022 Annual Report - Chapter 2.2.2 Business Development by Division - Crop Science // Bayer 2022 Sustainability Report - Focus on: Agriculture chapter
Ingredient Sourcing	Identification of principal crops and description of risks and opportunities presented by climate change	-	For more information: // <u>Bayer 2022 Sustainability Report</u> – Chapter 7.3 Climate Protection – Risk and Opportunity Analysis // Bayer 2022 TCFD Report <u>www.bayer.com/tcfd</u>
	Percentage of agricultural products sourced from regions with High or Extremely High Baseline Water Stress		Not applicable

Activity Metrics

SASB Activity Metric	SASB Code	e
Production by principal crop	FB-AG- 000.A	Not applicable
Number of processing facilities	FB-AG- 000.B	Not applicable
Total land area under active production	FB-AG- 000.C	Not applicable
Cost of agricultural products sourced externally	FB-AG- 000.D	Not applicable

Masthead

Published by Bayer AG, 51368 Leverkusen, Germany

Date of publication Tuesday, February 28, 2023

Public Affairs, Science, Sustainability & HSE Klaus Kunz Email: klaus.kunz@bayer.com

Sebastian Leins Email: sebastian.leins@bayer.com

Bayer on the internet: www.bayer.com

Forward-Looking Statements:

This publication may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.